112
Participants
Start Date
May 30, 2013
Primary Completion Date
December 6, 2021
Study Completion Date
December 14, 2021
E7777 9 mcg/kg
administered by intravenous (i.v.) infusion over 60 minutes (+/-10 minutes) on 5 consecutive days during every cycle of 21 days
Westmead Hospital, Westmead
Epworth Healthcare Freemasons, East Melbourne
Peter MacCallum Cancer Institute, East Melbourne
Columbia University Medical Center, New York
University of PittsburghMedical Center Presbyterian Shadyside, Pittsburgh
University of Pittsburgh Medical Center, Pittsburgh
Winship Cancer Institute of Emory University, Atlanta
University of Florida, Gainesville
H. Lee Moffitt Cancer Center, Tampa
University of South Florida College of Medicine, Tampa
University of Alabama at Birmingham, Dermatology at Whitaker Clinic, Birmingham
Northwestern Memorial Hospital, Chicago
Rush University Medical Center, Chicago
University of Arkansas for Medical Sciences, Little Rock
The University of TX MD Anderson Cancer Center, Houston
City of Hope Medical Center National Medical Center, Duarte
UC Irvine Health-Chao Family Comprehensive Cancer Center, Orange
Stanford University Cancer Center, Stanford
Yale University Cancer Center, New Haven
Dana Farber Cancer Institute, Boston
Hackensack University Medical Center, Hackensack
Auxilio Mutuo Cancer Center, San Juan
Collaborators (2)
Dr. Reddy's Laboratories Limited
INDUSTRY
Citius Pharmaceuticals, Inc.
INDUSTRY
Eisai Inc.
INDUSTRY